Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan.
Yokota S, Mori M, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, Takei S; Pediatric Rheumatology Association of Japan. Yokota S, et al. Among authors: tomiita m. Mod Rheumatol. 2010 Apr;20(2):107-13. doi: 10.1007/s10165-009-0259-9. Epub 2010 Jan 20. Mod Rheumatol. 2010. PMID: 20087751 Review.
Guidance on using tocilizumab for juvenile idiopathic arthritis.
Yokota S, Imagawa T, Takei S, Murata T, Tomiita M, Itoh Y, Fujikawa S, Mori M. Yokota S, et al. Among authors: tomiita m. Mod Rheumatol. 2011 Dec;21(6):563-71. doi: 10.1007/s10165-011-0464-1. Epub 2011 May 20. Mod Rheumatol. 2011. PMID: 21597951 Review.
Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: tomiita m. J Rheumatol. 2014 Apr;41(4):759-67. doi: 10.3899/jrheum.130690. Epub 2014 Mar 15. J Rheumatol. 2014. PMID: 24634205 Clinical Trial.
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, Shimizu M, Tomiita M, Seko N, Kitawaki T, Yokota S. Nishimura K, et al. Among authors: tomiita m. Mod Rheumatol. 2021 Jan;31(1):226-234. doi: 10.1080/14397595.2020.1783163. Epub 2020 Jul 29. Mod Rheumatol. 2021. PMID: 32552266 Free article. Clinical Trial.
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Among authors: tomiita m. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7. Lancet. 2008. PMID: 18358927 Clinical Trial.
61 results